


Express Mail No.: EV058075736US  
Date of Deposit: May 16, 2002

Please type a plus sign (+) in this box



RECEIVED

MAY 21 2002

Page 1 of 2

TECH CENTER 1600/2900

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Application Number	09/973,424
	Filing Date	10/09/01
	First Named Inventor	Prayaga
	Group Art Unit	1653
	Examiner Name	Not Assigned
	Attorney Docket Number	15966-585 CIP2(Cura-85 CIP2)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
<i>[Signature]</i>	B1*	WO 99/47674	Corixa Corp.	09/23/1999		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
<i>[Signature]</i>	C1*	Abdollahi et al. (1991). "Sequence and expression of a cDNA encoding MyD118: a novel myeloid differentiation primary response gene induced by multiple cytokines." <u>Oncogene</u> 6(1): 165-167.
	C2*	Aumailley and Gayraud (1998). "Structure and biological activity of the extracellular matrix." <u>J Mol Med</u> 76(3-4): 253-265.
	C3*	Bodey et al. (2000). "Review of thymic hormones in cancer diagnosis and treatment." <u>Int J Immunopharmacol</u> 22(4): 261-273.
	C4*	Bruckner-Tuderman and Bruckner (1998). "Genetic diseases of the extracellular matrix: more than just connective tissue disorders." <u>J Mol Med</u> 76(3-4): 226-237.
	C5*	GenBank Accession Number: X59292 (01/21/99)
	C6*	GenBank Accession Number: NP_065387 (11/02/00)
	C7*	Chan and Watt (1991). "eek and erk, new members of the eph subclass of receptor protein- tyrosine kinases." <u>Oncogene</u> 6(6): 1057-1061.
	C8*	Choi et al. (1999). "Characterization of ephrin-A1 and ephrin-A4 as ligands for the EphA8 receptor protein tyrosine kinase." <u>Mol Cells</u> 9(4): 440-445.
	C9*	Frisen et al. (1999). "Ephrins and their Eph receptors: multitasking directors of embryonic development." <u>Embo J</u> 18(19): 5159-5165.
	C10*	Hall (1995). "Thymosin beta-10 accelerates apoptosis." <u>Cell Mol Biol Res</u> 41(3): 167-180.
	C11*	Lacy et al. (1999). "Identification of FLRT1, FLRT2, and FLRT3: a novel family of transmembrane leucine-rich repeat proteins." <u>Genomics</u> 62(3): 417-426.
	C12*	Lin and Morrison-Bogorad (1991). "Cloning and characterization of a testis-specific thymosin beta 10 cDNA. Expression in post-meiotic male germ cells." <u>J Biol Chem</u> 266(34): 23347-23353.
	C13*	Muallem et al. (1995). "Actin filament disassembly is a sufficient final trigger for exocytosis in nonexcitable cells." <u>J Cell Biol</u> 128(4): 589-598.
	C14*	Genbank Accession Number: O09127 (05/30/00)
	C15*	Santelli et al. (1999). "Thymosin beta-10 gene overexpression is a general event in human carcinogenesis." <u>Am J Pathol</u> 155(3): 799-804.
<i>[Signature]</i>	C16*	Sztrolovics et al. (1999). "Resistance of small leucine-rich repeat proteoglycans to proteolytic

Express Mail No.: EV058075736US  
Date of Deposit: May 16, 2002

Page 2 of 2

OTHER PRIOR ART AND PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		degradation during interleukin-1-stimulated cartilage catabolism." <i>Biochem J</i> 339(Pt 3): 571-577.
	C17*	Sztrolovics et al. (1994). "Localization of the human fibromodulin gene (FMOD) to chromosome 1q32 and completion of the cDNA sequence." <i>Genomics</i> 23(3): 715-717.
	C18*	Wang et al. (1998). "Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4 [see comments]." <i>Cell</i> 93(5): 741-753.
	C19*	EMBL Database Accession Number: Z93023 (03/19/97).
	C20*	EMBL Database Accession Number: AA758513 (01/26/98).
	C21*	EMBL Database Accession Number: AL035703 (03/12/99).
	C22*	EMBL Database Accession Number: U72207 (12/25/96).
	C23*	EMBL Database Accession Number: AB040892 (05/23/00).
	C24*	EMBL Database Accession Number: AF007139 (02/09/98).
	C25*	EMBL Database Accession Number: AF169675 (01/31/00).
	C26*	EMBL Database Accession Number: AP000597 (10/15/99).
	C27*	Nagase et al. (2000). <i>DNA Res.</i> 7: 143-150.
	C28*	Park and Sanchez (1997). <i>Oncogene</i> 14: 533-542.
	C29*	Tureci, et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95: 7608-7613.
	C30*	Weternan, et al. (1993). <i>Int. J. Cancer</i> 53: 278-284.
	C31*	International Search Report for PCT/US 00/28474. Mailed on July 5, 2001.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/689,486, filed October 12, 2000, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).


Examiner Signature		Date Considered	12.11.03
--------------------	---	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Express Mail No. EV109727062US  
Date of Deposit: December 16, 2002

Page 1 of 1



Please type a plus sign (+) in this box

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

RECEIVED

DEC 19 2002

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/973,424
	<b>Filing Date</b>	10/09/2001
	<b>First Named Inventor</b>	Prayaga
	<b>Group Art Unit</b>	1653
	<b>Examiner Name</b>	Not Yet Assigned
	<b>Attorney Docket Number</b>	15966-585CIP2 (CURA-85CIP2)

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
AK	B2	WO	96/11016	Alpha 1 Biomedicals, Inc.	04/18/1996		
AK	B3	WO	01/29217	Curagen Corp.	04/26/2001		
AK	B4	WO	00/06190	Secretary of Health and Human Services, NIH	02/10/2002		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
AK	C32	Antonsson, et al. (1993). "Structure and deduced amino acid sequence of the human fibromodulin gene" <i>Biochemica Et Biophysica Acta</i> 1174(2):204-206.					
AK	C33	Chan, et al. (1991). "Eek and Erk, New Members of the Eph Subclass of Receptor Protein-tyrosine Kinases" <i>Oncogene, Basingstoke, Hants, GB</i> 6:1057-1061.					
AK	C34	McCreary, et al. (1998). "Sequence of a Human Kidney Complementary DNA clone Encoding Thymosin Beta-10" <i>Biochemical and Biophysical Research Communications</i> 152(2):862-866.					
AK	C35	International Search Report for PCT/US01/31498. Mailed on 10/24/2002					

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

<b>Examiner Signature</b>		<b>Date Considered</b>	12.11.03
---------------------------	--	------------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.